Full-Time

Territory Sales Manager

Sales, Medical Devices

Posted on 9/2/2025

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$120k/yr

+ Variable Compensation

No H1B Sponsorship

Knoxville, TN, USA

Hybrid

Candidate must live in or around the Knoxville, TN area.

Category
Sales & Account Management (1)
Requirements
  • Education: Bachelor’s degree or equivalent experience
  • 5+ years of outside sales/sales management experience. Medical device experience preferred
  • Strong track record of over-delivering revenue versus sales plan
  • Proficient in navigating and accelerating hospital and ASC product approval processes
  • Operating room experience required
  • Successful track record of launching new and disruptive technologies and well-versed and proficient in complex reimbursement environments
  • Compliance with relevant vaccination county, state, and federal rules
Responsibilities
  • Meet or exceed quarterly sales quota for the defined area.
  • Maintain a monthly and quarterly territory plan that outline territory sales objectives and areas of vulnerability.
  • Provide monthly forecasts for defined area.
  • Effectively communicate the value proposition of Calyxo products to customers.
  • Qualify, train, assess, and develop accounts to adopt Calyxo products as an integral part of their kidney stone practice with the goal of demonstrating high account adoption.
  • Communicate current market conditions and recommend improvements to the commercial process.
  • Partner with Professional Education to deliver outstanding clinical and training support to ensure physicians quickly become clinically independent.
  • Build and maintain relationships with key customers and KOLs within defined region.
  • Partner closely with the Regional Sales Manager, Sales team, and Marketing team to identify and prioritize customers for higher-level corporate relationships.
  • Partner with the Customer Service team to meet and exceed customer expectations.
  • Partner with the Regional Sales Manager and Finance team to ensure all required sales reporting forms are completed and submitted on time.
  • Provide support for the resolution of product complaints and/or safety issues.
  • Proactively support organizational goals and objectives, policies and procedures, Good Manufacturing Practices, and FDA regulations, including strict compliance with Calyxo’s Customer Relationship and the Sunshine Act policies.
  • Maintain a professional and credible image with key physicians, consultants, suppliers, and teammates.
  • Establish and maintain credentials (via RepTrax, Vendormate, etc) to enter and work in hospitals and other medical facilities as required by facility requirements.
  • Manage travel and expenses per approved budget.
  • Perform other duties as assigned.
  • Contribute to our culture of being collaborative, respectful, transparent, ethical, efficient, high- achieving, and fun!
Desired Qualifications
  • Medical device experience preferred
  • Thorough knowledge of urology and urology products and strong relationships with local urologists highly desired
  • Understanding of the treatment algorithm for patients with kidney stones preferred

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE